The purpose of the study is to evaluate whether Telmisartan can lower the pressure in the liver veins after 12 weeks of treatment. Participants will be randomly assigned to receive either Telmisartan or the placebo, and neither the participants nor the researchers will know who is receiving which treatment. This is known as a double-blind study. The study will last for 12 weeks, during which time participants will take the medication or placebo daily. The main goal is to see if there is a decrease in the pressure in the liver veins, which will be measured at the beginning and end of the study.

Throughout the study, participants will have regular check-ups to monitor their health and any changes in their condition. The researchers will also measure changes in liver and spleen stiffness, which are indicators of liver health. This study aims to provide valuable information on whether Telmisartan can be an effective treatment for reducing liver vein pressure in patients with these liver conditions.

The purpose of the study is to see if simvastatin can significantly reduce liver fibrosis in patients with chronic liver disease due to alcohol. Participants will receive either simvastatin or a placebo and will be monitored over a period of 24 months. During this time, the health of their liver will be assessed through various methods, including liver biopsies, which involve taking a small sample of liver tissue to examine under a microscope. The study will also look at changes in liver stiffness, which can be measured using special imaging techniques, and other markers in the blood that indicate liver health.

Throughout the study, researchers will also explore other aspects of liver health, such as changes in the gut microbiome, which is the community of bacteria living in the intestines, and markers of inflammation in the body. The safety and any side effects of simvastatin will be closely monitored to ensure the well-being of participants. This trial is designed to provide valuable insights into whether simvastatin can be a beneficial treatment for reducing liver damage in patients with alcoholic liver disease.

The purpose of the study is to determine if taking Orlistat for 24 weeks can significantly reduce the amount of fat in the liver compared to a control group. Participants will be randomly assigned to receive either Orlistat or a placebo. The study will last for about six months, during which participants will take the medication orally in the form of hard capsules. The main focus is to observe changes in liver fat content, but the study will also look at other health factors such as body weight, insulin sensitivity, blood sugar levels, and cholesterol levels.

Throughout the study, participants will have regular check-ups to monitor their health and the effects of the treatment. The goal is to see if Orlistat can help reduce liver fat and improve overall health in people with NAFLD and obesity. This research could provide valuable insights into managing liver health and related conditions in the future.

Participants in the study will be randomly assigned to receive either Zinc Acexamate or a placebo, which is a substance with no active medication. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual treatment or the placebo. This helps ensure that the results are not biased. The treatment will be taken orally, and the study will monitor the participants over a period to observe any changes in their condition.

The main goal is to determine if Zinc Acexamate can reduce the risk of serious liver-related events, such as liver failure, liver cancer, or the need for a liver transplant. By participating in this study, researchers hope to gather valuable information that could lead to better treatment options for people with chronic liver disease in the future.